Amanda Lanier

Biopharma financings June 2024

First half of 2024 sees biopharma financings nearing full-year 2023 total

July 9, 2024

Biopharma financings reached $70.09 billion in the first half of 2024, a 129% increase from the $30.57 billion raised in the first half of 2023. At more than $70 billion, this year's financings are already approaching the full-year total of $70.97 billion for 2023. June saw $7.57 billion in total financings, a decrease from $9.15 billion in May.

First half of 2024 marks 29% increase in med-tech fundraising year over year

July 9, 2024

By Amanda Lanier

In the first six months of 2024, the med-tech industry raised $13.84 billion, a 29% increase from the $10.75 billion collected during the first half of 2023. While May saw a significant $5.05 billion raised, the monthly total decreased to $1.14 billion in June.

Biopharma financings June 2024

First half of 2024 sees biopharma financings nearing full-year 2023 total

July 5, 2024

By Amanda Lanier

Biopharma financings reached $70.09 billion in the first half of 2024, a 129% increase from the $30.57 billion raised in the first half of 2023. At more than $70 billion, this year's financings are already approaching the full-year total of $70.97 billion for 2023. June saw $7.57 billion in total financings, a decrease from $9.15 billion in May.

Biopharma clinical updates May 2024

May’s 298 clinical trial updates led by Astrazeneca, Hutchmed and Novartis

July 2, 2024

By Amanda Lanier

In May 2024, BioWorld covered 298 updates across phase I-III clinical trials, surpassing March (261), February (236) and January (252), though falling short of April’s high of 323. Additionally, at the end of May BioWorld revised its reporting criteria for clinical trial updates, focusing mainly on data readouts and excluding trial initiations, enrollment changes and initial patient dosing, thereby impacting the update count relative to prior months.

Index insights

Design, Sarepta, Wave rise amid overall neurological index decline

July 1, 2024

By Amanda Lanier

In the first five months of 2024, the BioWorld Neurological Diseases Index (BNDI) saw a 10.35% decline, underperforming both the Nasdaq Biotechnology Index (NBI), which rose by 0.7%, and the Dow Jones Industrial Average (DJIA), which increased by 2.64%. This represents an additional drop for BNDI, which closed February with a 4.1% decline. In contrast, in 2023, the BNDI closed with a 4.36% increase, outperforming the NBI, which rose by 3.74%, but not matching the 13.7% rise seen in the DJIA.

Biopharma clinical updates May 2024

May’s 298 clinical trial updates led by Astrazeneca, Hutchmed and Novartis

June 28, 2024

By Amanda Lanier

In May 2024, BioWorld covered 298 updates across phase I-III clinical trials, surpassing March (261), February (236) and January (252), though falling short of April’s high of 323. Additionally, at the end of May BioWorld revised its reporting criteria for clinical trial updates, focusing mainly on data readouts and excluding trial initiations, enrollment changes and initial patient dosing, thereby impacting the update count relative to prior months.

FDA Approved stamp with pills, bottle, blister pack

Biopharma regulatory actions and approvals May 2024

Two Eylea biosimilars among 11 FDA drug approvals in May

June 25, 2024

By Amanda Lanier

In May, the U.S. FDA approved 11 new drugs, a significant drop from the 26 approvals in April, which was the sixth-highest monthly total since 2016. This also falls short of March’s record-setting 30 approvals, the highest number recorded by BioWorld.

Biopharma regulatory actions and approvals May 2024

Two Eylea biosimilars among 11 FDA drug approvals in May

June 21, 2024

By Amanda Lanier

In May, the U.S. FDA approved 11 new drugs, a significant drop from the 26 approvals in April, which was the sixth-highest monthly total since 2016. This also falls short of March’s record-setting 30 approvals, the highest number recorded by BioWorld.

Biopharma index outpaces market benchmarks with an 8% rise

June 21, 2024

By Amanda Lanier

The BioWorld Biopharmaceutical Index (BBI) saw an 8.15% increase at the close of May, outperforming the Dow Jones Industrial Average, which rose by 2.64%, and the Nasdaq Biotechnology Index, which was up by 0.7%. The BBI previously showed a strong performance in Q1, followed by a dip for all three indices in April, before all rebounded in May.

Biopharma deals May 2024

May biopharma deals hit $18.76B, up 23% from April

June 18, 2024

By Amanda Lanier

Biopharma deal value surged in May to $18.76 billion, up 23% from April's $15.28 billion. This increase follows March’s $8.29 billion and February’s $7.76 billion, although represents a decline from January’s $27.9 billion. The monthly average for 2024 stands at $15.64 billion, compared to the $18.14 billion monthly average in 2023. Meanwhile, the value of biopharma M&As rose to $4.75 billion in May, an increase from April’s $1.33 billion, which was the lowest figure in nearly a year.